{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2023-N-4225\" and posted_year = 2024 sorted by posted_date descending", "rows": [["FDA-2023-N-4225-0039", "FDA", "FDA-2023-N-4225", "Reference 37 Rosner DG Nondetected The Politics of Measurem in Talc 1971 1976 AJPH Vol 2019", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:04Z", null, 0, 0, "090000648688cadb"], ["FDA-2023-N-4225-0046", "FDA", "FDA-2023-N-4225", "PRIA Footnote Reference 1 Updating Value per Statistical Life (VSL) Estimates for Inflation and Changes in Real Income", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:46Z", null, 0, 0, "090000648688cafa"], ["FDA-2023-N-4225-0056", "FDA", "FDA-2023-N-4225", "PRIA Reference 8 Passport Beauty and Personal Care in the US", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:50Z", null, 0, 0, "090000648688cb05"], ["FDA-2023-N-4225-0002", "FDA", "FDA-2023-N-4225", "List of references 12 11 2024", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:49:21Z", null, 0, 0, "090000648688caae"], ["FDA-2023-N-4225-0028", "FDA", "FDA-2023-N-4225", "Reference 26 - Lowers H -Tabulation of Asbestos Related Terminology 2002", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:58Z", null, 0, 0, "090000648688cad1"], ["FDA-2023-N-4225-0029", "FDA", "FDA-2023-N-4225", "Reference 27 - Campbell WJ Selected Silicate Minerals and Their Asbestiform Varieties US Bureau of Mines Information Circular 8751- 1977", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:04Z", null, 0, 0, "090000648688cad2"], ["FDA-2023-N-4225-0043", "FDA", "FDA-2023-N-4225", "Reference 41 USP-NF General Chapter Prospectus 1901_ Theory and Practices of Asbestos Detection in PHarmaceutical Talc 2021", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:29Z", null, 0, 0, "090000648688cadf"], ["FDA-2023-N-4225-0059", "FDA", "FDA-2023-N-4225", "PRIA Reference 11 Malignant Mesothelioma and Its Non-Asbestos Causes", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:06Z", null, 0, 0, "090000648688cb08"], ["FDA-2023-N-4225-0018", "FDA", "FDA-2023-N-4225", "Reference 16 Translocation of inhaled asbestos fibers from the lung to other tissues.pdf Suzuki Y 1991", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:54Z", null, 0, 0, "090000648688cac8"], ["FDA-2023-N-4225-0052", "FDA", "FDA-2023-N-4225", "PRIA Reference 4 Method J 4-1 Asbestiform Amphibole Minerals in Cosmetic Talc", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:26Z", null, 0, 0, "090000648688cb00"], ["FDA-2023-N-4225-0054", "FDA", "FDA-2023-N-4225", "PRIA Reference 6 White Paper IWGACP Scientific Opinions on Testing Methods for Asbestos in Cosmetic Products Containing Talc", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:39Z", null, 0, 0, "090000648688cb03"], ["FDA-2023-N-4225-0004", "FDA", "FDA-2023-N-4225", "Reference 2 Where is Asbestos Found ATSDR - Naturally Occurring Asbestos", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:49:33Z", null, 0, 0, "090000648688cab0"], ["FDA-2023-N-4225-0019", "FDA", "FDA-2023-N-4225", "Reference 17 Fitzgerald Comparing Historical and Recent Accelerated Concerns Regarding Asbestos in Talc 2021", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:00Z", null, 0, 0, "090000648688cac9"], ["FDA-2023-N-4225-0021", "FDA", "FDA-2023-N-4225", "Reference 19 FDA In Brief_ FDA Releases Final Report of Talc-containing cosmetic products tested for asbestos", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:12Z", null, 0, 0, "090000648688cacb"], ["FDA-2023-N-4225-0051", "FDA", "FDA-2023-N-4225", "PRIA Reference 3 Asbestos in Commercial Cosmetic Talcum Powder as a Cause of Mesothelioma in Women", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:21Z", null, 0, 0, "090000648688caff"], ["FDA-2023-N-4225-0053", "FDA", "FDA-2023-N-4225", "PRIA Reference 5 The U.S. Pharmacopeial Convention Revision Bulletin Talc", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:32Z", null, 0, 0, "090000648688cb01"], ["FDA-2023-N-4225-0072", "FDA", "FDA-2023-N-4225", "PRIA Reference 24 Critical Review of the Association Between Perineal Use of Talc Powder and Risk of Ovarian Cancer", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:56:17Z", null, 0, 0, "090000648688cb18"], ["FDA-2023-N-4225-0074", "FDA", "FDA-2023-N-4225", "PRIA Reference 26 Some Pitfalls of Practical Benefit-Cost Analys", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:56:28Z", null, 0, 0, "090000648688cb1a"], ["FDA-2023-N-4225-0001", "FDA", "FDA-2023-N-4225", "Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2024-12-27T05:00:00Z", 2024, 12, "2024-12-27T05:00:00Z", "2025-03-28T03:59:59Z", "2025-03-29T01:00:19Z", "2024-30544", 0, 0, "090000648689150a"], ["FDA-2023-N-4225-0006", "FDA", "FDA-2023-N-4225", "Reference 4 Segrave Overview of the Geology of Cosmetic Talc Formation 2021", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:49:45Z", null, 0, 0, "090000648688cab2"], ["FDA-2023-N-4225-0008", "FDA", "FDA-2023-N-4225", "Reference 6 Toxicological Review of Libby Amphibole Asbestos EPA IRIS 2014", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:49:57Z", null, 0, 0, "090000648688cab4"], ["FDA-2023-N-4225-0010", "FDA", "FDA-2023-N-4225", "Reference 8 Toxicological Profile for Asbestos ATSDR 2001", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:08Z", null, 0, 0, "090000648688cab6"], ["FDA-2023-N-4225-0023", "FDA", "FDA-2023-N-4225", "Reference 21 Block Stimuli to the Revision Process Modernization of Asbestos Testing in Talc USP PF 40 4  2014", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:24Z", null, 0, 0, "090000648688caba"], ["FDA-2023-N-4225-0017", "FDA", "FDA-2023-N-4225", "Reference 15 Asbestos exposure and ovarian fiber burden.", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:49Z", null, 0, 0, "090000648688cac7"], ["FDA-2023-N-4225-0041", "FDA", "FDA-2023-N-4225", "Reference 39 USP CN Talc Detection of Asbestos in Pharmace Talc 1901 Theory and Practice of Asbestos Detection in Pharmace 2023..", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:18Z", null, 0, 0, "090000648688cadd"], ["FDA-2023-N-4225-0049", "FDA", "FDA-2023-N-4225", "PRIA Reference 1 National Toxicology Report on Carcinogens", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:10Z", null, 0, 0, "090000648688cafd"], ["FDA-2023-N-4225-0057", "FDA", "FDA-2023-N-4225", "PRIA Reference 9 Talc and Pyrophyllite Mineral Commodity Summary", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:54Z", null, 0, 0, "090000648688cb06"], ["FDA-2023-N-4225-0061", "FDA", "FDA-2023-N-4225", "PRIA Reference 13 Costs of Medical Care for Mesothelioma", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:17Z", null, 0, 0, "090000648688cb0d"], ["FDA-2023-N-4225-0064", "FDA", "FDA-2023-N-4225", "PRIA Reference 16 Cost of Care for the Initial Management of Ovarian Cancer", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:34Z", null, 0, 0, "090000648688cb10"], ["FDA-2023-N-4225-0066", "FDA", "FDA-2023-N-4225", "PRIA Reference 18 Guidelines for Regulatory Impact Analysis", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:45Z", null, 0, 0, "090000648688cb12"], ["FDA-2023-N-4225-0070", "FDA", "FDA-2023-N-4225", "PRIA Reference 22 Douching and Genital Talc Use Patterns of Use and Reliability of Self-reported Exposure", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:56:06Z", null, 0, 0, "090000648688cb16"], ["FDA-2023-N-4225-0009", "FDA", "FDA-2023-N-4225", "Reference 7 Filetti et al Update of in vitro  in vivo and ex vivo fluoro edenite effects of malignant mesothelioma 2020", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:02Z", null, 0, 0, "090000648688cab5"], ["FDA-2023-N-4225-0015", "FDA", "FDA-2023-N-4225", "Reference 13 IWGACP Appendices to White Paper January 13 2022", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:38Z", null, 0, 0, "090000648688cac5"], ["FDA-2023-N-4225-0067", "FDA", "FDA-2023-N-4225", "PRIA Reference 19 USP's Iterative Approach to Standards Development and the Emerging Standards", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:50Z", null, 0, 0, "090000648688cb13"], ["FDA-2023-N-4225-0014", "FDA", "FDA-2023-N-4225", "Reference 12 Asbestos hazards-and-safe-practice-for-clear-up-after-tsunami. 2006", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:33Z", null, 0, 0, "090000648688cac4"], ["FDA-2023-N-4225-0033", "FDA", "FDA-2023-N-4225", "Reference 31 - COPYRIGHT International Organization for Standardization ISO 22262-1-2012", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:27Z", null, 0, 0, "090000648688cad6"], ["FDA-2023-N-4225-0036", "FDA", "FDA-2023-N-4225", "Reference 34 - CIR Expert Panel Meeting March 18-19 2013 - Safety Assessment of Talc as Used in Cosmetics 2013", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:47Z", null, 0, 0, "090000648688cad8"], ["FDA-2023-N-4225-0045", "FDA", "FDA-2023-N-4225", "Talc PRIA Reference List", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:41Z", null, 0, 0, "090000648688caf9"], ["FDA-2023-N-4225-0062", "FDA", "FDA-2023-N-4225", "PRIA Reference 14 Lung Cancer Costs by Treatment Strategy and Phase of Care Among Patients Enrolled in Medicare", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:23Z", null, 0, 0, "090000648688cb0e"], ["FDA-2023-N-4225-0068", "FDA", "FDA-2023-N-4225", "PRIA Reference 20 Consolidated Financial Statements and Report of Independent Certified Public Accountants United States Pharmacopeial Convention and Subsidia", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:56Z", null, 0, 0, "090000648688cb14"], ["FDA-2023-N-4225-0013", "FDA", "FDA-2023-N-4225", "Reference 11 Asbestos - Overview _ Occupational Safety and Health Administration", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:27Z", null, 0, 0, "090000648688cac3"], ["FDA-2023-N-4225-0022", "FDA", "FDA-2023-N-4225", "Reference 20 Millette Procedure for the Analysis of Talc for Asbestos 2015", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:18Z", null, 0, 0, "090000648688cacc"], ["FDA-2023-N-4225-0025", "FDA", "FDA-2023-N-4225", "Reference 23 Peer review Report External Peer Review Comments and FDA Responses 2024", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:36Z", null, 0, 0, "090000648688cace"], ["FDA-2023-N-4225-0031", "FDA", "FDA-2023-N-4225", "Reference 29 Baumann Asbestos is not just asbestos_ an unrecognised health hazard 2013", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:16Z", null, 0, 0, "090000648688cad4"], ["FDA-2023-N-4225-0037", "FDA", "FDA-2023-N-4225", "Reference 35 Talc _ USP-NF Compendial Notices Intent to Revise Talc USP Monograph Asbestos Test Method 2020", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:52Z", null, 0, 0, "090000648688cad9"], ["FDA-2023-N-4225-0044", "FDA", "FDA-2023-N-4225", "Reference 42 Preliminary Regulatory Impact Analysis Asbestos in Talc PRIA", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:35Z", null, 0, 0, "090000648688caf8"], ["FDA-2023-N-4225-0050", "FDA", "FDA-2023-N-4225", "PRIA Reference 2 A Review of Human Carcinogens Part C Metals Arsenic Dusts and Fibres", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:16Z", null, 0, 0, "090000648688cafe"], ["FDA-2023-N-4225-0058", "FDA", "FDA-2023-N-4225", "PRIA Reference 10 Asbestos Contamination in Talc-Based Cosmetics An Invisible Cancer Risk", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:00Z", null, 0, 0, "090000648688cb07"], ["FDA-2023-N-4225-0069", "FDA", "FDA-2023-N-4225", "PRIA Reference 21 Sunscreen Drug Formulations for Over-the-Counter Human Use", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:56:01Z", null, 0, 0, "090000648688cb15"], ["FDA-2023-N-4225-0073", "FDA", "FDA-2023-N-4225", "PRIA Reference 25 Perineal Use of Talc and Risk of Ovarian Cancer", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:56:23Z", null, 0, 0, "090000648688cb19"], ["FDA-2023-N-4225-0003", "FDA", "FDA-2023-N-4225", "Reference 1 Ultramafic hosted talc magnesite deposits 2006", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:49:27Z", null, 0, 0, "090000648688caaf"], ["FDA-2023-N-4225-0011", "FDA", "FDA-2023-N-4225", "Reference 9 IARC_Monograph_Asbestos.2012", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:14Z", null, 0, 0, "090000648688cab7"], ["FDA-2023-N-4225-0034", "FDA", "FDA-2023-N-4225", "Reference 32 - International Organization for Standardization ISO 10312-2019", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:33Z", null, 0, 0, "090000648688cabd"], ["FDA-2023-N-4225-0027", "FDA", "FDA-2023-N-4225", "Reference 25 Miller E. A review of the mesotheliogenic potency of cleavage fragments found in talc", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:52Z", null, 0, 0, "090000648688cad0"], ["FDA-2023-N-4225-0030", "FDA", "FDA-2023-N-4225", "Reference 28 Van Gosen - A USGS Study of Talc Deposits and Associated Amphibole ....Southern Death Valley Region Californina 2004", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:09Z", null, 0, 0, "090000648688cad3"], ["FDA-2023-N-4225-0040", "FDA", "FDA-2023-N-4225", "Reference 38 USP Talc Absence of Asbestos Test method Official May 1 2022", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:12Z", null, 0, 0, "090000648688cadc"], ["FDA-2023-N-4225-0042", "FDA", "FDA-2023-N-4225", "Reference 40 General Chapter Prospectus 901_ Detection of Asbestos in Pharmaceutical Talc 2021", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:23Z", null, 0, 0, "090000648688cade"], ["FDA-2023-N-4225-0063", "FDA", "FDA-2023-N-4225", "PRIA Reference 15 Treatment Survival and Costs of Laryngeal Cancer Care in the Elderly", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:28Z", null, 0, 0, "090000648688cb0f"], ["FDA-2023-N-4225-0065", "FDA", "FDA-2023-N-4225", "PRIA Reference 17 Recall Cost Cast Studies", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:39Z", null, 0, 0, "090000648688cb11"], ["FDA-2023-N-4225-0071", "FDA", "FDA-2023-N-4225", "PRIA Reference 23 The Environmental Injustice of Beauty Framing Chemical Exposures from Beauty Products as a Health Disparities Concern", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:56:12Z", null, 0, 0, "090000648688cb17"], ["FDA-2023-N-4225-0024", "FDA", "FDA-2023-N-4225", "Reference 22 Interagency Workgroup for Asbestos in Consumer Products IWGACP- White Paper 2022", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:29Z", null, 0, 0, "090000648688cacd"], ["FDA-2023-N-4225-0026", "FDA", "FDA-2023-N-4225", "Reference 24 Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:41Z", null, 0, 0, "090000648688cacf"], ["FDA-2023-N-4225-0038", "FDA", "FDA-2023-N-4225", "Reference 36 ISO IEC Guide 2 2004. Standardization and related activities General vocabulary 2004", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:59Z", null, 0, 0, "090000648688cada"], ["FDA-2023-N-4225-0005", "FDA", "FDA-2023-N-4225", "Reference 3 Virta Asbestos Geology Mineralogy Mining and Uses 2002", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:49:39Z", null, 0, 0, "090000648688cab1"], ["FDA-2023-N-4225-0007", "FDA", "FDA-2023-N-4225", "Reference 5 Asbestos. In Report on Carcinogens Fiftheenth Edition 2021", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:49:51Z", null, 0, 0, "090000648688cab3"], ["FDA-2023-N-4225-0016", "FDA", "FDA-2023-N-4225", "Reference 14 Ingested mineral fibers elimination in human urine Science 204 195-8 1979", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:44Z", null, 0, 0, "090000648688cac6"], ["FDA-2023-N-4225-0020", "FDA", "FDA-2023-N-4225", "Reference 18 FDA Talc Previous Activity", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:51:06Z", null, 0, 0, "090000648688caca"], ["FDA-2023-N-4225-0035", "FDA", "FDA-2023-N-4225", "Reference 33 IMA Amphibole Supergroup Mineral information data and localities", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:39Z", null, 0, 0, "090000648688cad7"], ["FDA-2023-N-4225-0048", "FDA", "FDA-2023-N-4225", "PRIA Footnote Reference 3 A Population-level Approach to Distributional Weighting", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:57Z", null, 0, 0, "090000648688cafc"], ["FDA-2023-N-4225-0060", "FDA", "FDA-2023-N-4225", "PRIA Reference 12 Under-Reporting of Adverse Drug Reactions A Systematic Review", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:55:12Z", null, 0, 0, "090000648688cb09"], ["FDA-2023-N-4225-0012", "FDA", "FDA-2023-N-4225", "Reference 10 Asbestos Selected Cancers NAS 2006", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:50:20Z", null, 0, 0, "090000648688cac2"], ["FDA-2023-N-4225-0032", "FDA", "FDA-2023-N-4225", "Reference 30 - National Institute for Occupational Safety and Health 2011", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:52:21Z", null, 0, 0, "090000648688cad5"], ["FDA-2023-N-4225-0047", "FDA", "FDA-2023-N-4225", "PRIA Footnote Reference 2 Circular A-4", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:53:52Z", null, 0, 0, "090000648688cafb"], ["FDA-2023-N-4225-0055", "FDA", "FDA-2023-N-4225", "PRIA Reference 7 Latent Period for Malignant Mesothelioma of Occupational Origin", "Supporting & Related Material", "Background Material", "2024-12-27T05:00:00Z", 2024, 12, null, null, "2024-12-30T02:54:44Z", null, 0, 0, "090000648688cb04"]], "truncated": false, "filtered_table_rows_count": 74, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2023-N-4225", "p1": "2024"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024", "results": [{"value": "FDA", "label": "FDA", "count": 74, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 73, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&document_type=Proposed+Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024", "results": [{"value": 2024, "label": 2024, "count": 74, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&_facet=subtype"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2023-N-4225&posted_year=2024&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 2966.5591928642243, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}